

# CV Sciences Certificate of Analysis



*This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.*

**SAMPLE ID:**

**PRODUCT NAME:**

Strength:

Lot Number:

Expiration Date:

**CANNABINOIDS\***

**MG/UNIT**

**METHOD**

CBD

CBDA

d9-THC

THCA-A

d8-THC

THCV

CBDV

CBDVA

CBGA

CBG

CBN

CBC

CBL

Total Cannabinoids

Sample Size

THC by Mass

**HEAVY METALS\***

**STATUS (PASS/FAIL)**

**METHOD**

Arsenic

Cadmium

Mercury

Lead

# CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES**	STATUS (PASS/FAIL)	METHOD
Total Pesticides		
Mycotoxins	Pass	

RESIDUAL SOLVENTS**	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.†

†Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

\*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Anresco Laboratories Sample ID #:

\*\*Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

## QUALITY APPROVAL

Prepared By / Date	Approved By / Date	Status
Vandana Kothari	 <small>DocuSigned by Vandana Kothari</small> <small>I approve this document</small> <small>08-Jun-2023   08:39 PDT</small> <small>87A410FF03248738900BEED0868E359</small>	





# Certificate of Analysis

**CV Sciences, Inc.**

10070 Barnes Canyon Road  
San Diego, CA 92121  
Vandana Kothari

Sample

**2305DBL0095.1161**

Batch FP-23-0075  
Lot 37036121-1

Ordered 6/2/2023

Completed 6/7/2023

**plusCBD 15mg 60ct softgel SKU 107 exp 05/25**

Cannabinoids				
	<b>19.44</b>	<b>4.583</b>	<b>0.424</b>	
Total CBD (mg/unit)	% Total CBD		Unit weight (g)	
Cannabinoid	LOQ %	Mass %	Mass mg/g	Concentration
CBD	0.0133	4.583	45.83	<div style="width: 45.83%;"></div>
CBDA	0.0133	<LOQ	<LOQ	
d9-THC	0.0133	0.037	0.37	
THCA-A	0.0133	<LOQ	<LOQ	
d8-THC	0.0133	<LOQ	<LOQ	
THCV	0.0133	<LOQ	<LOQ	
CBDV	0.0133	0.040	0.40	
CBDVA	0.0133	<LOQ	<LOQ	
CBGA	0.0133	<LOQ	<LOQ	
CBG	0.0133	<LOQ	<LOQ	
CBN	0.0133	<LOQ	<LOQ	
CBC	0.0133	0.073	0.73	
CBL	0.0133	<LOQ	<LOQ	

Microbiology				
Quantitative Analysis	Status	Sample	LOQ	Limit
	Pass/Fail	CFU/g	CFU/g	CFU/g
Mold/Mildew/Yeast	PASS	<LOQ	80	10,000
Enterobacteriaceae	PASS	<LOQ	80	1,000
Aerobic Bacteria	PASS	<LOQ	800	100,000
Coliforms	PASS	<LOQ	80	1,000
Qualitative Analysis		Detected or Not-detected		
E. Coli	PASS	Not-detected		
Salmonella	PASS	Not-detected		
Pseudomonas	PASS	Not-detected		

Heavy Metals				
Compound	Status	Sample	LOQ	Limit
	Pass/Fail	PPB	PPB	PPB
Arsenic	PASS	<LOQ	118	1500
Cadmium	PASS	<LOQ	118	500
Mercury	PASS	<LOQ	118	1000
Lead	PASS	<LOQ	118	500

- The hemp extract is the product of a batch tested by the independent testing laboratory;
- The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of a random sample of the batch; and
- The batch does not contain contaminants unsafe for human consumption.\*



*[Signature]*

Glen Marquez  
Director

*[Signature]*

Sherri Defreese  
Quality Control



4439 Polaris Ave.  
Las Vegas, NV 89103  
(702)729-5180  
www.dblabslv.com

The reported result is based on a sample weight with the applicable moisture content for that sample. LOQ = Limit of Quantitation. NA = Not Analyzed. ND = Not Detected. PGR = Plant Growth Regulator. Unless otherwise stated all quality control samples performed within specifications established by the Laboratory. This product has been tested by DB Labs, LLC (MMEH 61887736101164525768) using valid testing methodologies and a quality system as required by Nevada state law. Values reported relate only to the product tested. DB Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. \*Tested analytes and limits were set by the customer. This Certificate shall not be reproduced except in full, without the written approval of DB Labs.

June 07, 2023

**CV SCIENCES, INC.**

9530 Padgett Street, Suite 107  
 San Diego, CA 92126

Order No. 545110  
 Sample No. 1162212

## SAMPLE INFORMATION

**Description** FP-23-0075 plusCBD 15mg 60ct softgel SKU 107 exp 05/25  
**Lot Number** 37036121-1  
**Category (Type)** Non-Inhalable Edible (Capsule)  
**Received** June 02, 2023

## ANALYTICAL RESULTS

**Analysis** Residual Solvent Screen ✔ Pass  
**Instrument** Gas Chromatography Mass Spectrometry (GC/MS)  
**Method** MF-CHEM-32  
**Analysis Date** June 02, 2023 to June 07, 2023

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.2/0.5	ND	1	Pass
Acetone	67/200	ND	5000	Pass
Acetonitrile	67/200	ND	410	Pass
Benzene	0.2/0.5	ND	1	Pass
n-Butane	67/200	ND	5000	Pass
Chloroform	0.2/0.5	ND	1	Pass
Ethanol	67/200	ND	5000	Pass
Ethyl acetate	67/200	ND	5000	Pass
Ethyl ether	67/200	ND	5000	Pass
Ethylene oxide	0.2/0.5	ND	1	Pass
n-Heptane	67/200	ND	5000	Pass
n-Hexane	67/200	ND	290	Pass
Isopropyl alcohol	67/200	ND	5000	Pass
Methanol	67/200	ND	3000	Pass
Methylene chloride	0.2/0.5	ND	1	Pass
n-Pentane	67/200	ND	5000	Pass
Propane	67/200	ND	5000	Pass
Toluene	67/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	67/200	ND	2170	Pass
Trichloroethylene	0.2/0.5	ND	1	Pass

Reported by  
**Anresco, Inc.**

ND = None Detected




Jordean Vargas  
 Analyst III

June 07, 2023

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

June 07, 2023

**CV SCIENCES, INC.**

9530 Padgett Street, Suite 107  
 San Diego, CA 92126

Order No. 545110  
 Sample No. 1162212

## SAMPLE INFORMATION

**Description** FP-23-0075 plusCBD 15mg 60ct softgel SKU 107 exp 05/25  
**Lot Number** 37036121-1  
**Category (Type)** Non-Inhalable Edible (Capsule)  
**Received** June 02, 2023

## ANALYTICAL RESULTS

**Analysis** Pesticide Screen ✔ Pass  
**Instrument** Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)  
**Method** MF-CHEM-13  
**Analysis Date** June 02, 2023 to June 07, 2023

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.02/0.06	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.02/0.06	ND	0.02	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.08	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.02/0.06	ND	0.02	Pass
DDVP (Dichlorvos)	0.02/0.06	ND	0.02	Pass
Diazinon	0.02/0.06	ND	0.2	Pass
Dimethoate	0.02/0.06	ND	0.02	Pass
Dimethomorph	0.02/0.06	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.02/0.06	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Fonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.02/0.06	ND	5.0	Pass
Metalaxyl	0.02/0.06	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.02/0.06	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.02/0.06	ND	0.5	Pass
Oxamyl	0.02/0.06	ND	0.2	Pass
Pacllobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.04/0.10	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.02/0.06	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.02/0.06	ND	0.02	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.02/0.06	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.02/0.06	ND	0.02	Pass
Tebuconazole	0.02/0.06	<LOQ (0.043)	2.0	Pass
Thiacloprid	0.02/0.06	ND	0.02	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	<LOQ (0.027)	30.0	Pass

Reported by  
**Anresco, Inc.**

ND = None Detected



Alyssa Tabuca  
 Analyst I

June 07, 2023

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

June 07, 2023

**CV SCIENCES, INC.**

9530 Padgett Street, Suite 107  
 San Diego, CA 92126

Order No. 545110  
 Sample No. 1162212

## SAMPLE INFORMATION

**Description** FP-23-0075 plusCBD 15mg 60ct softgel SKU 107 exp 05/25  
**Lot Number** 37036121-1  
**Category (Type)** Non-Inhalable Edible (Capsule)  
**Received** June 02, 2023

## ANALYTICAL RESULTS

**Analysis** Mycotoxins Screen ✔ Pass  
**Instrument** Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)  
**Method** MF-CHEM-13  
**Analysis Date** June 02, 2023 to June 07, 2023

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by  
**Anresco, Inc.**

ND = None Detected



Alyssa Tabucan  
 Analyst I

June 07, 2023

If there are any questions with this report, please contact "[compliance@anresco.com](mailto:compliance@anresco.com)".

### Certificate Of Completion

Envelope Id: 021889F13BFE4540A66E653B9B8492A1	Status: Completed
Subject: FP-23-0075 15MG 60CT sOFTGEL COA	
Source Envelope:	
Document Pages: 7	Signatures: 1
Certificate Pages: 4	Initials: 0
AutoNav: Enabled	Envelope Originator:
Enveloped Stamping: Enabled	Vandana Kothari
Time Zone: (UTC-08:00) Pacific Time (US & Canada)	vandana.kothari@cvsciences.com
	IP Address: 64.207.219.71

### Record Tracking

Status: Original	Holder: Vandana Kothari	Location: DocuSign
6/8/2023 8:52:05 AM	vandana.kothari@cvsciences.com	

### Signer Events

Vandana Kothari  
 vandana.kothari@cvsciences.com  
 DIRECTOR OF QUALITY  
 CV Sciences - Part 11  
 Security Level: Email, Account Authentication (Required)

### Signature

Signature Adoption: Pre-selected Style  
 Signature ID:  
 87A410FF-F032-4873-8900-BEED0868E359  
 Using IP Address: 107.132.215.12  
  
 With Signing Authentication via DocuSign password  
 With Signing Reasons (on each tab):  
 I approve this document

### Timestamp

Sent: 6/8/2023 8:54:55 AM  
 Viewed: 6/8/2023 8:58:41 AM  
 Signed: 6/8/2023 8:59:22 AM

**Electronic Record and Signature Disclosure:**  
 Accepted: 6/15/2022 3:47:18 PM  
 ID: e1aa8e52-a247-4777-bd8b-6bacc8ae66c7

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	6/8/2023 8:54:55 AM
Certified Delivered	Security Checked	6/8/2023 8:58:41 AM
Signing Complete	Security Checked	6/8/2023 8:59:22 AM
Completed	Security Checked	6/8/2023 8:59:22 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		



## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, CV Sciences - Part 11 (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact CV Sciences - Part 11:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [vandana.kothari@cvsciences.com](mailto:vandana.kothari@cvsciences.com)

### **To advise CV Sciences - Part 11 of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [vandana.kothari@cvsciences.com](mailto:vandana.kothari@cvsciences.com) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

### **To request paper copies from CV Sciences - Part 11**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [vandana.kothari@cvsciences.com](mailto:vandana.kothari@cvsciences.com) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

### **To withdraw your consent with CV Sciences - Part 11**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to vandana.kothari@cvsciences.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify CV Sciences - Part 11 as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by CV Sciences - Part 11 during the course of your relationship with CV Sciences - Part 11.